natgillin/translations-raw huggingface dataset:
The invention also relates to a method of encapsulating at least one agent in silk fibroin. The method comprises (a) exposing a silk fibroin solution with an ultrasonication treatment for a period of time to initiate gelation; and (b) introducing the agent into the silk fibroin before substantial gelation occurs in the silk fibroin, thus forming a silk-fibroin encapsulated agent. 
Postupak kapsuliranja barem jednog sredstva u fibroin svile, obuhvaća: dovođenje u doticaj otopine fibroina svile s obradom pomoću ultrazvukom kroz vrijeme od oko 5 sekundi do oko 60 sekundi radi započinjanja geliranja; i uvođenje sredst(a)va u otopinu fibroina svile prije nego što dođe do značajnijeg geliranja u otopini fibroina svile; kako bi se dobilo sredstvo kapsulirano u fibroinu svile.
In some embodiments, the cyclizing agent can have the following formula: where each of X and Y is independently an unsubstituted or substituted imidazolyl, benzimidazolyl or benzotriazolyl. 
H, F, benzil, (Cy-Cg)alkil, (C2-Cg)alkenil ili (C2-Cg)alkinil; a svaki od X i Y je neovisno nesupstituirani ili supstituirani imidazolil, benzimidazolil ili benzotriazolil.
The present invention provides a compound or composition for use in the treatment of cancer, and more preferably a cancer selected from lung cancer, including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer and gastric cancer. 
Sjedinjenje, kompozicija ili dozni oblik u skladu sa patentnim zahtjevom 7, gdje je rak odabran od raka pluća uključujući rak pluća malih stanica i rak pluća nemalih stanica, rak debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika i raka želuca.
Process according to one of the claims 1 to 6, wherein the at least one water-soluble acid of step b) has a pKa from 0 to 6, preferably has a pKa from 0 to 2.5. 
Postupak prema jednom od zahtjeva 1 do 5, naznačen time da barem jedna kiselina koja se otapa u vodi iz koraka b) ima pKa od 0 do 6, poželjno ima pKa od 0 do 2.5.
The raising pressure in the pressure chamber will force the bottle upwards in the direction of the lower pressure of the surroundings, until the upper part of the flange of the bottle abuts on the lower surface of the rosette. 
Rastući pritisak u tlačnoj komori će prisiliti bocu da se pomakne prema gore u smjeru nižeg pritiska okruženja, sve dok gornji dio prirubnice boce dođe na donju površinu rozete.
Moreover, these behavioural deficits were found to be reversed by adenosine A2A receptor antagonists (Minor et al., 2001, Behav Brain Res 120: 230-212). 
Čak štoviše, taj bihevjoralni manjak je pokazan kao povratan/reverzibilan primjenom antagonista adenozin A2a-teceptora (Minor et al., 2001, Behav Brain Res 120: 230-212).
reacting the compound of formula (XVIII-S) with a compound of formula (XIX-S), wherein Q0 is bromo or iodo; to yield the corresponding compound of formula (XX-S); 
(XX-8) reagiranje spoja formule (XVIII-S) sa spojem formule (XIX-S), gdje je Q" bromo ili jodo; kako bi se dobio odgovarajući spoj formule (XX-S);
A hybridoma comprising a rearranged immunoglobulin light chain gene sequence derived from the mouse of claim 1, the rearranged sequence comprising a hVλ gene segment, a hJVλ gene segment and a mouse Ck gene at an endogenous mouse immunoglobulin k light chain locus, wherein at said locus the k intronic enhancer element upstream of the Ck gene (designated Eki) and the 3' k enhancer downstream of the Ck gene (designated Ek3') are maintained, where the hybridoma expresses an antibody comprising a light chain that comprises a rearranged human Vλ-Jλ sequence and a mouse Ck sequence. 
Hibridom koji sadrži preuređenu sekvencu gena imunoglobulinskog lakog lanca dobivenu iz miša prema patentnom zahtjevu 1, preuređenu sekvencu koja sadrži segment gena hV2, segment gena hJA i mišji gen CK na lokusu endogenog mišjeg imunoglobulinskog lakog lanca K, naznačen time, što se na spomenutom lokusu održava element intronskog pojačivača K uzvodno od gena CK (označen kao EKi) 1 pojačivač 3' K nizvodno od gena CK (označen kao EK3'), pri čemu hibridom izražava antitijelo koje sadrži laki lanac koji sadrži preuređenu humanu sekvencu VA-JA i mišju sekvencu CK.
Solvates do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. 
Solvati ne doprinose značajno fiziološkoj aktivnosti ili toksičnosti spojeva i kao takvi funkcioniraju kao farmakološki ekvivalenti.
The compound of claim 1, wherein the compound is one of the following compounds: 
Tvar, gdje je tvar jedna od sljedećih tvari: vara?
The communication device according to claim 12 wherein DVRBs with non-consecutive DVRB numbers are mapped to PRBs, which are adjacent to each other in the frequency domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
The invention also concerns a hydrocracking process employing the hydrotreatment process of the invention, in which said hydrotreated effluent is brought into contact, in the presence of hydrogen and under hydrocracking operating conditions, with at least one hydrocracking catalyst so as to obtain a hydrocracked effluent. 
Postupak hidrokrekiranja koji koristi postupak hidroobrade prema zahtjevima 1 do 13, naznačen time da se navedeni hidroobrađeni efluent dovodi u kontakt, u prisutnosti vodika i pod uvjetima rada hidrokrekiranja, s barem jednim katalizatorom za hidrokrekiranje kako bi se dobio hidrokrekirani efluent.
represents C1-3-alkyl, methylamino, ethylamino, or dimethylamino; represents hydroxymethyl, hydroxyethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, aminoethyl, 2-methylamino-ethyl, or 2-dimethylamino-ethyl; k represents the integer 1, 2, or 3; 
predstavlja C1-3-alkil, metilamino, etilamino ili dimetilamino; predstavlja hidroksimetil, hidroksietil, aminometil, metilaminometil, dimetilaminometil, aminoetil, 2-metilamino-etil ili 2-dimetilamino-etil; k predstavlja cijeli broj 1, 2 ili 3; m predstavlja cijeli broj 1 ili 2; n predstavlja 0, 1 ili 2; i
Use of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a sequential or separate co-administrable medicament, in particular the combination product or kit according to the invention, for the preventive or curative treatment of an inflammatory pulmonary disease. Use according to any one of claims 15 or 16, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, ROFLUMILAST N-Oxide, CILOMILAST, AWD-12-281, TOFIMILAST, TETOMILAST, LIRIMILAST, L-869298, OGLEMILAST, 2-{4-[(4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-acetamide and a pharmaceutically acceptable salt of these compounds. 
Uporaba PDE4-inhibitora i inhibitora reduktaze HMG-CoA, naznačena time, da je za proizvodnju dodatnog lijeka koji se daje uzastopno ili odvojeno uz prvi lijek, posebno kombiniranog proizvoda ili garniture prema izumu, za prevenciju ili liječenje upalne plućne bolesti, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol.
Operative conditions of the Spray Dryer: 
Datum objave europske prijave patenata:
In addition, ET-743 exhibits limited aqueous solubility, and its stability, particularly in biocompatible forms and formulations, is difficult to predict and achieve. 
Osim toga, ET-743 pokazuje ograničenu topljivost u vodi, a njegovu stabilnost, posebno u biokompatibilnim oblicima i smjesama, teško je predvidjeti i postići.
The nucleic acid of claim 7, wherein the regulatory element is a rodent regulatory element, such as a mouse regulatory element. 
Nukleinska kiselina prema zahtjevu 6, naznačena time, da ne-ljudski regulacijski element je glodarski regulacijski element kao što je primjerice mišji regulacijski element.
a therapeutically effective amount of an adenosine diphosphate (ADP) antagonist or P2Y12 antagonist to inhibit platelet aggregation, wherein said ADP or P2Y12 antagonist is clopidogrel or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer, or polymorph thereof; and 
terapijski učinkovitu količinu antagonista adenozin difosfata (ADP) ili antagonista P2Y12 za inhibiciju agregacije trombocita, gdje je navedeni antagonist ADP ili P2Y12 klopidogrel ili njegova farmaceutski prihvatljiva sol, njegov solvat, hidrat, enantiomer ili polimorf; i
10 Number of Scans 
Broj međunarodne objave:
The device set forth in claim 3 wherein said air passage includes a damper valve (30) for operator adjustment of air flow to said plenum when said control valve is open. 
Uređaj u skladu s patentnim zahtjevom 3, naznačen time što navedeni kanal za zrak ima jedan prigušni ventil (30) koji omogućava osobi koja poslužuje uređaj da namješta strujanje zraka prema navedenom razdjelniku za zrak, kada je navedeni regulacijski ventil otvoren.
Composition for use according to claim 1, wherein the dihydropyrimidine dehydrogenase inhibitor is 2,4-dihydroxy-5-chloropyridine. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da inhibitor dehidrogenaze dihidropirimidina je 2,4dihidroksi-5-kloropiridin.
Best VCI scores of human VK compared with 158 VK 
Najbolji VCI režultati za humani VK u usporedbi sa 158 VK iv
Biotin for use according to claim 7, characterized in that the excipients are chosen from the group consisting of talc, microcrystalline cellulose, lactose and mannose. 
Biotin za uporabu prema patentnom zahtjevu 11, naznačen time što su pomoćne tvari izabrane iz skupine koja se sastoji od talka, mikrokristalne celuloze, laktoze i manoze.
The valve element 5 further comprises at its other end a second axial channel 12 connected with a second radial aperture 13 and passes through a second gasket 14 . 
Nadalje, na svom drugom kraju element ventila 5 obuhvaća drugi aksijalan kanal 12 povezan s drugom radijalnom rupicom 13 i prolazi kroz drugu brtvu 14.
It is thus becoming a widely held view in the medicinal chemistry field that drugs capable of blocking the pre-synaptosomal uptake of serotonin in the brain, thereby alleviating serotonin abnormalities at adjacent post-synaptic receptor sites, will comprise an additional major category of antidepressant agents. 
Tako je postalo široko prihvaćeno gledište u medicinskoj kemiji da će lijekovi koji mogu blokirati presinaptosomalnu potrošnju serotonina, pa tako ublažavaju abnormalnosti serotonina na susjednim postsinaptičkim reccptorski mjestima, činiti dopunsku glavnu kategoriju antidepresivnih sredstava.
A method for the preparation of the compound of formula I or a salt thereof comprising reacting a compound of formula VIa (i.e. 
uklanjanje zaštite Spoja VIII da se dobije Spoj I, gdje su Spoj VII i VIII: [image] Postupak pripreme Spoja I ili njegove soli koji obuhvaća reakciju spoja formule VIa (tj.
Preferred pigments include, but are not limited to, titanium dioxide, iron oxide, and vegetable dyes. 
Povoljni pigmenti uljučuju, ali nisu ograničeni na, titan dioksid, željezo oksid i biljne boje.
The compound claim 1, wherein R6 is selected from the group consisting of —OH, C1-C6 alkoxy, —OC(O)—C1-C6 alkyl, and —OC(O)phenyl. The compound of claim 20, wherein R6 is —OH. The compound of claim 1, wherein R7 is C1-C6 alkyl. 
Spoj prema bilo kojem od zahtjeva 1-11, pri čemu Rs je odabran od skupine koja se sastoji od -OH, C;-Cg alkoksi, -OC(O)-C1-Cg alkila, 1 -OC(O)fenila, izborno pri čemu Re je -OH; i/ili pri čemu R; je Ci-C4 alkil, izborno pri čemu R; je -CHa.
In another aspect, the invention deals with a method for preventing and/or treating of the remyelination blockage in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype comprising the administration of at least one Nitric Oxyde radical inhibitory drug to a human being. 
barem jedan inhibitorni lijek radikala dušikovog oksida; kao kombinacijski proizvod za istodobnu, odvojenu ili primjenu raširenu tijekom vremena za uporabu u sprječavanju 1/ili liječenju remijelinizacijske blokade u bolesti koja je povezana s ekspresijom HER V-W proteina ovojnice (ENV), posebice njegovog MSRV podtipa, naznačen time što:
The invention further concerns the embodiment of the above-described CD3-binding molecules wherein the molecule is a CD3-binding diabody that comprises a first polypeptide chain and a second polypeptide chain, the chains being covalently bonded to one another, wherein: 
CD3-vezujuća molekula prema bilo kojem od patentnih zahtjeva 1-3, naznačena time što navedena molekula je CD3-vezujuće diatijelo koje sadrži prvi polipeptidni lanac i drugi polipeptidni lanac, pri čemu su navedeni lanci kovalentno međusobno vezani, pri čemu:
Preferably a large scale cultivation is performed at a volume of at least 1001, more preferably of at least 5001, most preferably of at least 10001 up to a volume of 20,000 1. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 1 19 do 22, naznačen time, da se kultivacija izvodi pri volumenu od najmanje 100 1, poželjnije najmanje 500 1, najpoželjnije najmanje 1000 1.
Pharmaceutical Compositions The crystalline hydrochloride salt forms of the invention are typically administered to a patient in the form of a pharmaceutical composition. 
Farmaceutski pripravak, naznačen time, da sadrži farmaceutski prihvatljiv nosač i spoj u obliku kristalne soli iz bilo kojeg od patentnih zahtjeva 1 do 12.
Prepared from 4-methoxy-benzenethiol and 2-bromo-4-fluoro-1-iodo-benzene (prepared from 2-bromo-4-fluoro-phenylamine by diazotization according to the general procedure by Tunney and Stille J. Org. 
Pripravljen iz 4-metoksi-benzentiola i 2- bromo-4-fluoro-1-jodo benzena (pripravljenog iz 2-bromo-4-fluoro-fenilamina diazotizacijom prema postupku opisanom u Tunney i Stillie, J. Org.
The air intake openings are covered with shutters attached to the top of the lid with a connecting mechanism. 
Otvori za ulaz zraka su pokriveni sa zaklopcima pričvršćenim na gornji dio poklopca pomoću spojnog mehanizma.
“cycloalkyl” means any mono- or bi-cyclic, non-aromatic, carbocyclic group containing from 3 to 10 ring members, 
"cikloalkil" znači bilo koja mono- ili bi-ciklička, nearomatska, karbociklička skupina koja sadržava od 3 do 10 članova prstena, -
A process for producing a compound represented by the formula (I-1) or its salt: wherein 
Postupak za proizvodnju piridil-triazolopirimidin derivata predstavljen formulom (I-1), ili njegova sol,
The composition of embodiment 2, wherein the inflammatory disease is of the small intestine, colon or rectum. 
Kompozicija za upotrebu prema zahtjevu 2, gdje je upalna bolest tankog crijeva, debelog crijeva ili rektuma.
to receive fluid from the first fluid source in that both are arranged to communicate with the first fluid source via a flow path which does not include any said phase contact device. 
da primi fluid iz prvog izvora fluida time što su oba raspoređena kako bi komunicirali sa prvim izvorom tekućine preko putanje protoka koja ne obuhvaća bilo koji navedeni faznokontaktni uređaj.
a VL chain with at least 95%, 96%, 97%, 98 or 99% identity to the amino acid sequence set forth in SEQ ID NO: 188, wherein the VL comprises no more than one amino acid substitution within the CDRs relative to the VL CDR1 amino acid sequence set forth in SEQ ID NO: 197, the VL CDR2 amino acid sequence set forth in SEQ ID NO: 199, and the VL CDR3 amino acid sequence set forth in SEQ ID NO:201. 
VL lanac sa najmanje 95%, 96%, 97%, 98 ili 99% identičnosti sa amino kiselinskom sekvencom navedenom u SEQ ID NO: 151, gdje VL sadrži ne više od jedne amino kiselinske supstitucije unutar CDR regiona u odnosu na VL CDR1 amino kiselinsku sekvencu navedenu u SEQ ID NO: 160, VL CDR2 amino kiselinsku sekvencu navedenu u SEQ ID NO: 162, i VL CDR3 amino kiselinsku sekvencu navedenu u SEQ ID NO: 164.
It is a further aspect of the present invention to provide a method for making a host cell for production of a heterodimeric Ig-like molecule, the method comprising the step of introducing into said host cell nucleic acid sequences encoding at least a first and a second CH3-domain comprising polypeptide chain, wherein said first CH3 domain-comprising polypeptide chain comprises at least one substitution of a neutral amino acid residue by a positively charged amino acid residue and wherein said second CH3 domain-comprising polypeptide chain comprises at least one substitution of a neutral amino acid residue by a negatively charged amino acid residue, wherein said nucleic acid sequences are introduced consecutively or concomitantly. 
Postupak za pripremu stanice domaćina za proizvodnju najmanje dva različita antitijela, pri čemu postupak sadrži korak uvođenja u navedenu stanicu domaćina sekvenci nukleinske kiseline koje kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizinski (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije, pri čemu navedene sekvence nukleinske kiseline su uvedene uzastopno ili istovremeno.
An expression vector comprising the DNA molecule according to claim 7. 
Vektor ekspresije koji sadrži DNK molekulu sukladno patentnom zahtjevu 7.
An aqueous formulation comprising a viscogenic agent, moxifloxacin or a salt thereof, and isopropyl myristate (IPM), wherein said formulation is flowable and has a viscosity less than 100 Pa*s at 25°C; wherein said formulation, after application to the tympanic membrane of the ear of a subject, forms a gel that has a yield stress sufficient to maintain said formulation against the tympanic membrane; and wherein said moxifloxacin transfers across the tympanic membrane and into the middle ear space when the formulation is applied to the tympanic membrane. 
Vodena formulacija, naznačena time što sadrži viskogeno sredstvo, moksifloksacin, ili njegovu sol, te izopropil- miristat (IPM), gdje je navedena formulacija tekuća i ima viskoznost manju od 100 Pa*s na 25 "C; gdje navedena formulacija, nakon primjene na membranu bubnjića u uhu subjekta, tvori gel koji ima elastičnu čvrstoću dovoljnu za zadržavanje navedene formulacije na membrani bubnjića; 1 gdje navedeni moksifloksacin prolazi kroz membranu bubnjića i u prostor srednjeg uha kada se formulaciju primijenjuje na membranu bubnjića.
The pharmaceutical composition of claim 15, wherein the film-coating is red, yellow, or pink. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, pri čemu je filmski premaz crven, žut ili ružičast.
The deuterium-substituted or isotopically labeled compound according to claim 4 or a pharmacologically acceptable salt thereof, or a solvate or hydrate thereof, or a deuterium-substituted derivative thereof, wherein the term "optionally having substituent(s)" has the meaning defined in claim 1, and wherein R1 is a hydrogen atom, a hydroxy group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a halo-C1 to C6 alkyl group, a hydroxy C1 to C6 alkyl group, a carboxy C1 to C6 alkyl group, a carbamoyl C1 to C6 alkyl group, a mono C1 to C6 alkylcarbamoyl C1 to C6 alkyl group, a di-C1 to C6 alkylcarbamoyl C1 to C6 alkyl group, an aminosulfonyl C1 to C6 alkyl group, an aromatic heterocyclic C1 to C3 alkyl group optionally having substituent(s), or a phenyl C1 to C3 alkyl group optionally having substituent(s); 
Spoj u skladu sa patentnim zahtjevom 4 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje izraz "po izboru ima supstituent(e)" ima značenje definirano u patentnom zahtjevu 1, i gdje R1 je atom vodika, hidroksi grupa, C1 do C6 alkil grupa, C1 do C6 alkoksi grupa, halo-C1 do C6 alkil grupa, hidroksi C1 do C6 alkil grupa, karboksi C1 do C6 alkil grupa, karbamoil C1 do C6 alkil grupa, mono C1 do C6 alkilkarbamoil C1 do C6 alkil grupa, di-C1 do C6 alkilkarbamoil C1 do C6 alkil grupa, aminosulfonil C1 do C6 alkil grupa, aromatična heterociklična C1 do C3 alkil grupa koja po izboru ima supstituent(e), ili fenil C1 do C3 alkil grupa koja po izboru ima supstituent(e);
A compound of formula Ib: wherein: 
Spoj s formulom Ib:
or RC and RD together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C1-4 alkyl; 
ili RC i RD zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila;
The solid formulation according to any of claims 2 to 8, characterized in that the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, glyceryl behenate, polyethylene glycol, stearic acid and talc. 
Kruti pripravak prema bilo kojem od zahtjeva 2 do 8, naznačen time, da je lubrikant odabran iz skupine koju čine magnezijev stearat, kalcijev stearat, gliceril behenat, polietilen glikol, stearinska kiselina 1 talk.
The composition according to any one of claims 1 to 5, wherein the one or more EO-PO block copolymer is poloxamer 407, the one or more protein agents is serum albumin, and the one or more carbohydrate agents is trehalose. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je jedan ili više EO-PO blok-kopolimera poloksamer 407, jedno ili više proteinskih sredstava je seralbumin, a jedno ili više ugljikohidratnih sredstava je trehaloza.
Solid supports recycled by a method of the present invention allow obtaining a protein productivity level comparable to the productivity level obtained with non-recycled solid support. 
Krute potpore koje se recikliraju s pomoću postupka iz ovoga izuma omogućavaju postizanje razine proizvodnje proteina koja je usporediva s razinom produktivnosti koja je dobivena s pomoću krutih potpora koje se ne recikliraju.
The antibody of claim 1 covalently attached to a cytotoxic agent. The antibody covalently attached to a cytotoxic agent of claim 3, wherein the cytotoxic agent is selected from a toxin, a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme. 
Imunokonjugat, naznačen time, da obuhvaća protutijelo genetskog inženjeringa cisteinom prema zahtjevu 11, kovalentno priključeno na citotoksično sredstvo, pri čemu je to citotoksično sredstvo po želji odabrano od sljedećih: toksin, kemoterapeutsko sredstvo, skupina ljekovitog sredstva, antibiotik, radioaktivni izotop i nukleolitički enzim.
It has been established that asenapine is a very potent dopamine and serotonin antagonist with antipsychotic activity. 
Zaključeno je da je asenapin veoma snažan antagonist dopamina i serotonina s antipsihotičnom aktivnošću.
A system according to claim 4, wherein said EMR tuner is a manually controlled trombone tuner. A system according to claim 4, wherein said EMR tuner is an automatically controlled EMR tuner. 
Sustav prema Zahtjevu 4, gdje je navedeni uređaj (210) za podešavanje elektromagnetnog zračenja (EMR) ručno kontrolirani trombonski podešivač ili automatski kontrolirani EMR podešivač.
Toluene (2500 mL) is added, and the solution washed carefully with 10% NaHCO3 (280 g in 2800 mL water). 
Doda se toluen (2500 ml), a otopinu pažljivo ispere 10 %-tnom otopinom NaHCO; (280 g u 2800 ml vode).
The modified Rv3616c protein according to claim 1, comprising the amino acid sequence of SEQ ID No: 169. 
Modificirani protein Rv3616c u skladu s patentnim zahtjevom 1, naznačen time što ima aminokiselinski slijed sa SEQ ID No: 169.